Business Wire

TRINAMIC

7.11.2016 16:32:35 CET | Business Wire | Press release

Share
Trinamic’s New Generation of Stepper Motor Drivers Link Optimized Power Control and Simplified Application

Trinamic Motion Control GmbH & Co. KG, a leading supplier of semiconductors, electronics and mechatronic solutions in the fields of motor and motion control, is proud to announce the arrival of a new family of high-performance semiconductor components for stepper motor control. The TMC2208-LA and TMC2224-LA are monolithic components with integrated circuit breakers for up to 1.2A RMS, and optimal power controllers for noiseless, sinusoidal control of the motor phases. Above all, both components were designed with the goal of easy application in mind. Trinamic will present the drives to the public at Electronica 2016, in Hall A4 at booth 513.

"Developers are under increasing pressure to shorten development cycles and bring new products on the market faster," explains Michael Randt, founder and CEO of Trinamic. "Our new family of drivers has been specially developed to help make the development process as short and as simple as possible."

Enhanced by the flexible microPlyer interpolater unit, the components offer a resolution of up to 256 microsteps-per-full-step to achieve perfect sinusoidal control - even with low-resolution motion controllers. Further development of Trinamic's stealthChop technology, which was introduced two years ago, has all but eliminated motor noise at low speeds, making the precise control of stepper motors not only possible, but affordable for application in environments that demand absolute silence, e.g. office buildings and residential areas.

Due to the immense popularity of stealthChop technology, the components have been designed for compatibility with existing 3D printer electronics. With stealthChop there is no need for costly redesign.

Both components feature a step/direction source for fully autonomous operation. Configuration is achieved via digital inputs.

The components will be available at a price of USD 1.22 at quantities of 1000 as a QFN28 (5x5) package in the first quarter of 2017. To accelerate the design process, Trinamic offers complete end-to-end evaluation kits. The development boards are open-source hardware and freely available for use as a reference design.

About Trinamic

Trinamic, headquartered in Hamburg, provides integrated circuits and motor control modules to customers worldwide. The company's application-driven approach and in-depth understanding of their customers' needs allow them to offer solutions which simplify and shorten the design phase, resulting in significant cost savings, decreased resource allocation and a reduced total cost of ownership. Trinamic's customers benefit from the company's rich expertise in motor physics and extensive portfolio of intellectual property (IP) acquired through many years of applied experience and success. Product development at Trinamic focuses entirely on miniaturizing form factor, increasing efficiency and maximizing the safety and reliability of their products and, thereby, the systems in which they're used.

The company is fully committed to providing energy efficient solutions. Industry-leading technologies such as Trinamic's patented coolStep™ products offer user-friendliness, precise stepper motor control and, above all, energy savings.

The Trinamic Motion Control Language (TMCL) facilitates the development of motor control applications, enabling shorter development cycles and rapid product release.

Over 20 years of experience and a traditional German ownership structure with private shareholders ensure the long-term availability of their products and components.

From the headquarters in Hamburg, Germany, Trinamic products are sold via a worldwide distribution network.

Printable graphics and an English-language version of this press release are available at:

http://www.trinamic.com/company/press/

Contact:

Trinamic
Jonas P. Proeger, +49 (0) 40 514 806-0
Marketing Director
proeger@trinamic.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye